Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.504
-0.096 (-16.02%)
At close: Nov 22, 2024, 4:00 PM
0.520
+0.016 (3.20%)
After-hours: Nov 22, 2024, 7:59 PM EST

Lineage Cell Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Market Capitalization
95191199413264133
Upgrade
Market Cap Growth
-17.21%-4.09%-51.84%56.44%98.01%19.78%
Upgrade
Enterprise Value
64151134349228101
Upgrade
Last Close Price
0.501.091.172.451.760.89
Upgrade
PS Ratio
10.6321.3213.5395.13144.5737.93
Upgrade
PB Ratio
1.443.082.764.542.781.20
Upgrade
P/TBV Ratio
19.0530.8412.4511.896.862.47
Upgrade
P/FCF Ratio
--307.85---
Upgrade
P/OCF Ratio
--187.79---
Upgrade
EV/Sales Ratio
7.3216.889.1180.50124.7028.82
Upgrade
EV/FCF Ratio
--207.31---
Upgrade
Debt / Equity Ratio
0.040.050.050.030.040.05
Upgrade
Debt / FCF Ratio
--6.03---
Upgrade
Asset Turnover
0.090.080.100.030.020.03
Upgrade
Quick Ratio
2.392.023.062.325.354.78
Upgrade
Current Ratio
2.482.143.162.375.668.86
Upgrade
Return on Equity (ROE)
-30.50%-32.07%-32.37%-46.52%-20.05%-11.62%
Upgrade
Return on Assets (ROA)
-11.84%-11.80%-9.44%-21.78%-14.16%-18.59%
Upgrade
Return on Capital (ROIC)
-17.48%-18.82%-16.60%-31.93%-15.35%-20.02%
Upgrade
Earnings Yield
-21.13%-11.26%-13.21%-10.42%-7.82%-8.78%
Upgrade
FCF Yield
-24.23%-15.33%0.32%-5.79%-7.51%-24.29%
Upgrade
Buyback Yield / Dilution
-7.29%-1.69%-3.22%-9.64%-3.10%-14.68%
Upgrade
Total Shareholder Return
-7.29%-1.69%-3.22%-9.64%-3.10%-14.68%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.